Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim

BMC Veterinary Research

Research Article

Aleksandra Chirek¹  Barbara Kohn¹  Sina Rehbein¹  Abdulgabar Salama²  Gürkan Bal² 

[1] FB Veterinärmedizin, Klinik für Kleine Haustiere, Freie Universität Berlin, Oertzenweg 19 b, 14163, Berlin, Germany;Institut für Transfusionsmedizin, Charité – Universitätsklinikum, Augustenburger Platz 1, 13353, Berlin, Germany;

关键词: Immune thrombocytopenia;    ITP;    Dog;    Romiplostim;    Thrombopoietin;    mpl;   

DOI  :  10.1186/s12917-016-0718-4

 received in 2015-11-17, accepted in 2016-06-01,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundImmune thrombocytopenia (ITP) in dogs is analogous to that in humans. Romiplostim, a novel thrombopoietin receptor (TPO-R) agonist, is currently used for the treatment of refractory ITP in humans, but not in dogs. Here, we describe the response to romiplostim in five dogs with refractory ITP. Five dogs with severe and refractory ITP (three primary and two secondary) received romiplostim subcutaneously. Four dogs were administered 3–5 μg/kg and one dog received 10–13 μg/kg body weight once weekly.ResultsRomiplostim was well-tolerated and administration was associated with an increase in platelet counts in all five dogs. Four of the five dogs entered remission and relapses were not observed over a follow-up period of 3–10 months.ConclusionsRomiplostim is effective in the treatment of ITP in dogs at least as well as in humans. This finding may help to develop and use new therapeutics for ITP in dogs and humans.

【 授权许可】

CC BY   
© The Author(s). 2016